NASDAQ:PMCB Nuvilex (PMCB) Stock Price, News & Analysis $1.04 -0.01 (-1.33%) As of 06/27/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Nuvilex Stock (NASDAQ:PMCB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Nuvilex alerts:Sign Up Key Stats Today's Range$1.02▼$1.0550-Day Range$1.00▼$1.2952-Week Range$1.00▼$2.42Volume5,335 shsAverage Volume19,361 shsMarket Capitalization$7.07 millionP/E Ratio1.39Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewPharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.Read More… Nuvilex Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks39th Percentile Overall ScorePMCB MarketRank™: Nuvilex scored higher than 39% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Nuvilex. Earnings and Valuation1.9 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Nuvilex is 1.39, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.02.Price to Earnings Ratio vs. SectorThe P/E ratio of Nuvilex is 1.39, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.21.Price to Book Value per Share RatioNuvilex has a P/B Ratio of 0.31. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Nuvilex's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.35% of the float of Nuvilex has been sold short.Short Interest Ratio / Days to CoverNuvilex has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nuvilex has recently increased by 29.88%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNuvilex does not currently pay a dividend.Dividend GrowthNuvilex does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.35% of the float of Nuvilex has been sold short.Short Interest Ratio / Days to CoverNuvilex has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nuvilex has recently increased by 29.88%, indicating that investor sentiment is decreasing significantly. News and Social Media3.8 / 5News SentimentN/A News SentimentNuvilex has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.94 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Nuvilex this week, compared to 0 articles on an average week.Search Interest1 people have searched for PMCB on MarketBeat in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Nuvilex insiders have not sold or bought any company stock.Percentage Held by Insiders10.20% of the stock of Nuvilex is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 34.24% of the stock of Nuvilex is held by institutions.Read more about Nuvilex's insider trading history. Receive PMCB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nuvilex and its competitors with MarketBeat's FREE daily newsletter. Email Address PMCB Stock News HeadlinesMyMD Pharmaceuticals Secures Strategic InvestmentsMay 21, 2024 | businesswire.comPharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory DiseaseMay 21, 2024 | businesswire.comMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.June 29 at 2:00 AM | American Alternative (Ad)PMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q2 2024December 18, 2023 | msn.comCompanies Like PharmaCyte Biotech (NASDAQ:PMCB) Are In A Position To Invest In GrowthDecember 15, 2023 | finance.yahoo.comPharmaCyte Biotech Inc PMCBDecember 5, 2023 | morningstar.comMPharmaCyte Biotech Invests In Femasys - Quick FactsNovember 15, 2023 | markets.businessinsider.comFemasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte BiotechNovember 15, 2023 | finance.yahoo.comSee More Headlines PMCB Stock Analysis - Frequently Asked Questions How have PMCB shares performed this year? Nuvilex's stock was trading at $1.57 at the beginning of 2025. Since then, PMCB shares have decreased by 34.4% and is now trading at $1.03. View the best growth stocks for 2025 here. How were Nuvilex's earnings last quarter? Nuvilex Inc. (NASDAQ:PMCB) issued its earnings results on Monday, March, 17th. The company reported ($0.10) earnings per share for the quarter. How do I buy shares of Nuvilex? Shares of PMCB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nuvilex own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nuvilex investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), ASML (ASML), GE Aerospace (GE), Oracle (ORCL) and Nokia (NOK). Company Calendar Last Earnings3/17/2025Today6/29/2025Next Earnings (Estimated)8/11/2025Fiscal Year End4/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PMCB CIK1157075 Webpharmacyte.com Phone917-595-2850Fax917-595-2851Employees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.74 Trailing P/E Ratio1.39 Forward P/E RatioN/A P/E GrowthN/ANet Income$330 thousand Net MarginsN/A Pretax MarginN/A Return on Equity0.51% Return on Assets0.35% Debt Debt-to-Equity RatioN/A Current Ratio14.21 Quick Ratio14.21 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.27 per share Price / Book0.31Miscellaneous Outstanding Shares6,860,000Free Float6,164,000Market Cap$7.07 million OptionableOptionable Beta-0.44 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:PMCB) was last updated on 6/29/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvilex Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvilex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.